Status:
COMPLETED
Treatment of Epiretinal Membranes With Ranibizumab
Lead Sponsor:
Queen's University
Conditions:
Epiretinal Membrane
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
Eligibility Criteria
Inclusion
- symptomatic idiopathic epiretinal membrane
Exclusion
- vision worse than 6/18 and fit for surgery
- prior vitreoretinal surgery or injection
- diabetes
- any past or current form of retinal vein occlusion or neovascularization
- age-related macular degeneration
- other condition causing significant limitation of visual potential
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01238393
Start Date
November 1 2010
End Date
January 1 2012
Last Update
January 13 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen's University, Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2